IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v67y2004i2p129-136.html
   My bibliography  Save this article

Satisfaction with and access to community care of the chronically ill in Israel's health system

Author

Listed:
  • Bentur, Netta
  • Gross, Revital
  • Brammli-Greenberg, Shuli

Abstract

No abstract is available for this item.

Suggested Citation

  • Bentur, Netta & Gross, Revital & Brammli-Greenberg, Shuli, 2004. "Satisfaction with and access to community care of the chronically ill in Israel's health system," Health Policy, Elsevier, vol. 67(2), pages 129-136, February.
    • Handle: RePEc:eee:hepoli:v:67:y:2004:i:2:p:129-136
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0168-8510(03)00086-1
    Download Restriction: Full text for ScienceDirect subscribers only
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Noyce, Peter R. & Huttin, Christine & Atella, Vicenzo & Brenner, Gerhard & Haaijer-Ruskamp, Flora M. & Hedvall, Maj-Britt & Mechtler, Reli, 2000. "The cost of prescription medicines to patients," Health Policy, Elsevier, vol. 52(2), pages 129-145, June.
    2. Williams, Brian, 1994. "Patient satisfaction: A valid concept?," Social Science & Medicine, Elsevier, vol. 38(4), pages 509-516, February.
    3. Scherer, F.M., 2000. "The pharmaceutical industry," Handbook of Health Economics, in: A. J. Culyer & J. P. Newhouse (ed.), Handbook of Health Economics, edition 1, volume 1, chapter 25, pages 1297-1336, Elsevier.
    4. Greene, Michele G. & Adelman, Ronald D. & Friedmann, Erika & Charon, Rita, 1994. "Older patient satisfaction with communication during an initial medical encounter," Social Science & Medicine, Elsevier, vol. 38(9), pages 1279-1288, May.
    5. Lundberg, Lena & Johannesson, Magnus & Isacson, Dag G. L. & Borgquist, Lars, 1998. "Effects of user charges on the use of prescription medicines in different socio-economic groups," Health Policy, Elsevier, vol. 44(2), pages 123-134, May.
    6. repec:mpr:mprres:3123 is not listed on IDEAS
    7. Evans, R.G. & Barer, M.L., 1995. "User Fees for Health Care: Why a Bad Idea Keeps Coming Back (Or, What's Health Got to Do with It?)," Centre for Health Services and Policy Research 95:8r, University of British Columbia - Centre for Health Services and Policy Research..
    8. Gross, Revital & Rosen, Bruce & Chinitz, David, 1998. "Evaluating the Israeli health care reform: strategy, challenges and lessons," Health Policy, Elsevier, vol. 45(2), pages 99-117, August.
    9. A. J. Culyer & J. P. Newhouse (ed.), 2000. "Handbook of Health Economics," Handbook of Health Economics, Elsevier, edition 1, volume 1, number 1.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Polluste, Kaja & Kalda, Ruth & Lember, Margus, 2007. "Satisfaction with the access to the health services of the people with chronic conditions in Estonia," Health Policy, Elsevier, vol. 82(1), pages 51-61, June.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Jiménez-Rubio, Dolores & Hernández-Quevedo, Cristina, 2010. "Explaining the demand for pharmaceuticals in Spain: Are there differences in drug consumption between foreigners and the Spanish population?," Health Policy, Elsevier, vol. 97(2-3), pages 217-224, October.
    2. Brekke, Kurt R. & Holmas, Tor Helge & Straume, Odd Rune, 2011. "Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment," Journal of Public Economics, Elsevier, vol. 95(7), pages 624-638.
    3. Christian Garavaglia & Franco Malerba & Luigi Orsenigo & Michele Pezzoni, 2013. "Technological Regimes and Demand Structure in the Evolution of the Pharmaceutical Industry," Economic Complexity and Evolution, in: Andreas Pyka & Esben Sloth Andersen (ed.), Long Term Economic Development, edition 127, pages 61-94, Springer.
    4. Brekke, Kurt R. & Kuhn, Michael, 2006. "Direct to consumer advertising in pharmaceutical markets," Journal of Health Economics, Elsevier, vol. 25(1), pages 102-130, January.
    5. Herz, Benedikt & Mejer, Malwina, 2020. "The effect of design protection on price and price dispersion: Evidence from automotive spare parts," MPRA Paper 109645, University Library of Munich, Germany, revised 01 Sep 2021.
    6. Havas, Attila, 2010. "Diversity in firms’ innovation strategies and activities: Main findings of interviews and implications in the context of the Hungarian national," MPRA Paper 55852, University Library of Munich, Germany.
    7. Martin Gaynor & Kate Ho & Robert J. Town, 2015. "The Industrial Organization of Health-Care Markets," Journal of Economic Literature, American Economic Association, vol. 53(2), pages 235-284, June.
    8. Cabiedes Miragaya, Laura, 2013. "Nuevas perspectivas sobre el precio de los medicamentos: El caso español/New Perspectives on Drug Pricing: The Spanish Case," Estudios de Economia Aplicada, Estudios de Economia Aplicada, vol. 31, pages 397-416, Septiembr.
    9. Ines Ayadi & Houssem Eddine Chebbi & Younes Boujelbene, 2009. "Investigating Generic and Brand Name Pharmaceutical’s Market Shares and Prices in Tunisia," Working Papers 497, Economic Research Forum, revised Jul 2009.
    10. Vincenzo Atella & Karen Hassell & Ellen Schafheutle & Marjorie C. Weiss & Peter R. Noyce, 2003. "Cost to the Patient or Cost to the Healthcare System? Which one Matters the Most for GP Prescribing Decisions? A UK-Italy Comparison," CEIS Research Paper 1, Tor Vergata University, CEIS.
    11. DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2003. "The price of innovation: new estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 151-185, March.
    12. Kurt R. Brekke & Odd Rune Straume, 2008. "Pharmaceutical Patents: Incentives for R&D or Marketing?," CESifo Working Paper Series 2433, CESifo.
    13. Gloria Allione & Raffaello Bronzini & Claire Giordano, 2020. "Recent export developments in the pharmaceutical sector in Italy and in the Lazio region," Questioni di Economia e Finanza (Occasional Papers) 566, Bank of Italy, Economic Research and International Relations Area.
    14. Ismo Linnosmaa & Raine Hermans & Taru Hallinen, 2004. "Price-cost margin in the pharmaceutical industry," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 5(2), pages 122-128, May.
    15. Linnosmaa, Ismo & Hermans, Raine & Kauhanen, Taru, 2002. "Price-Cost Margin in the Pharmaneutical Industry: Empirical Evidence from Finland," Discussion Papers 818, The Research Institute of the Finnish Economy.
    16. Hermans, Raine & Linnosmaa, Ismo, 2003. "Price Markups and R&D Inputs: The Pharmaceutical Industry in Finland and the USA," Discussion Papers 877, The Research Institute of the Finnish Economy.
    17. Herz, Benedikt & Mejer, Malwina, 2021. "The effect of design protection on price and price dispersion: Evidence from automotive spare parts," International Journal of Industrial Organization, Elsevier, vol. 79(C).
    18. Vincenzo Atella & Peter R. Noyce & Ellen Schafheutle & Karen Hassell, 2005. "Affordability of Medicines and Patients' Cost Reduction Behaviors: Empirical Evidence Based on SUR Estimates from Italy and the United Kingdom," CEIS Research Paper 71, Tor Vergata University, CEIS.
    19. Hermans, Raine, . "International Mega-Trends and Growth Prospects of the Finnish Bio-technology Industry - Essays on New Economic Geography, Market Structure of the Pharmaceutical Industry, Sources of Financing, Intelle," ETLA A, The Research Institute of the Finnish Economy, number 40, June.
    20. repec:dau:papers:123456789/3608 is not listed on IDEAS
    21. Ute Laermann-Nguyen & Martin Backfisch, 2021. "Innovation crisis in the pharmaceutical industry? A survey," SN Business & Economics, Springer, vol. 1(12), pages 1-37, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:67:y:2004:i:2:p:129-136. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.